

Hiroshi Kobayashi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6283372/publications.pdf>

Version: 2024-02-01

228
papers

4,744
citations

87888

38
h-index

144013

57
g-index

231
all docs

231
docs citations

231
times ranked

5017
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Targets for Nonhormonal Treatment Based on a Multistep Process of Adenomyosis Development. <i>Reproductive Sciences</i> , 2023, 30, 743-760.	2.5	5
2	Effects of iron-related compounds and bilirubin on redox homeostasis in endometriosis and its malignant transformations. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2022, 43, 187-192.	0.7	3
3	Proposal for adenomyosis classification based on the endometriosis phenotype. <i>Medical Hypotheses</i> , 2022, 158, 110742.	1.5	0
4	Revisiting therapeutic strategies for ovarian cancer by focusing on redox homeostasis (Review). <i>Oncology Letters</i> , 2022, 23, 80.	1.8	3
5	Macrophages Protect Endometriotic Cells Against Oxidative Damage Through a Cross-Talk Mechanism. <i>Reproductive Sciences</i> , 2022, 29, 2165-2178.	2.5	2
6	Feasibility of a mobile cardiotocogram device for fetal heart rate self-monitoring in low-risk singleton pregnant women. <i>Journal of Obstetrics and Gynaecology Research</i> , 2022, 48, 385-392.	1.3	3
7	The Comparison of Three Predictive Indexes to Discriminate Malignant Ovarian Tumors from Benign Ovarian Endometrioma: The Characteristics and Efficacy. <i>Diagnostics</i> , 2022, 12, 1212.	2.6	4
8	Tissue Factor Pathway Inhibitor 2: A Novel Biomarker for Predicting Asymptomatic Venous Thromboembolism in Patients with Epithelial Ovarian Cancer. <i>Gynecologic and Obstetric Investigation</i> , 2022, 87, 133-140.	1.6	5
9	Possible association between adenomyosis and disseminated intravascular coagulation and thromboembolism: A systematic review. <i>World Academy of Sciences Journal</i> , 2022, 4, .	0.6	2
10	Hypoxia Promotes Extravillous Trophoblast Cell Invasion through the Hypoxia-Inducible Factor Urokinase-Type Plasminogen Activator Receptor Pathway. <i>Gynecologic and Obstetric Investigation</i> , 2022, 87, 232-241.	1.6	4
11	Tissue factor pathway inhibitor 2: A potential diagnostic marker for discriminating benign from malignant ovarian tumors. <i>Journal of Obstetrics and Gynaecology Research</i> , 2022, 48, 2442-2451.	1.3	3
12	Guideline for Gynecological Practice in Japan: Japan Society of Obstetrics and Gynecology and Japan Association of Obstetricians and Gynecologists 2020 edition. <i>Journal of Obstetrics and Gynaecology Research</i> , 2021, 47, 5-25.	1.3	23
13	Rapid multiplex PCR assay for simultaneous detection of <i>Neisseria gonorrhoeae</i> and <i>Chlamydia trachomatis</i> in genitourinary samples: A 30-minute assay. <i>Journal of Microbiological Methods</i> , 2021, 180, 106103.	1.6	4
14	Relationship between Cyst Fluid Concentrations of Iron and Severity of Dysmenorrhea in Patients with Ovarian Endometrioma. <i>Gynecologic and Obstetric Investigation</i> , 2021, 86, 185-192.	1.6	6
15	Validation of magnetic resonance relaxometry R2 value and cyst fluid iron level for diagnosis of ovarian endometrioma. <i>Redox Report</i> , 2021, 26, 105-110.	4.5	2
16	Dynamic changes in the levels of maternal serum squamous cell carcinoma antigen, a potential biomarker of amniotic fluid embolism, before and after delivery in relation to the mode of delivery. <i>World Academy of Sciences Journal</i> , 2021, 3, .	0.6	0
17	Nonhormonal Treatment for Endometriosis Focusing on Redox Imbalance. <i>Gynecologic and Obstetric Investigation</i> , 2021, 86, 1-12.	1.6	8
18	Immunohistochemical Expression Status of p53, CD44v9, and Ki-67 in a Series of Fallopian Tube Lesions of High-grade Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2021, 40, 419-426.	1.4	4

#	ARTICLE	IF	CITATIONS
19	Reprogramming of glucose metabolism of cumulus cells and oocytes and its therapeutic significance. <i>Reproductive Sciences</i> , 2021, , 1.	2.5	14
20	Revisiting estrogen-dependent signaling pathways in endometriosis: Potential targets for non-hormonal therapeutics. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 258, 103-110.	1.1	11
21	Relationship between magnetic resonance imagingâ€based classification of adenomyosis and disease severity. <i>Journal of Obstetrics and Gynaecology Research</i> , 2021, 47, 2251-2260.	1.3	9
22	CCNE1 Is a Putative Therapeutic Target for ARID1A-Mutated Ovarian Clear Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5869.	4.1	7
23	Prognostic value of pre-treatment systemic immune-inflammation index in patients with endometrial cancer. <i>PLoS ONE</i> , 2021, 16, e0248871.	2.5	11
24	Validation of tissue factor pathway inhibitor 2 as a specific biomarker for preoperative prediction of clear cell carcinoma of the ovary. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1336-1344.	2.2	13
25	Toward an understanding of tissue factor pathway inhibitorâ€2 as a novel serodiagnostic marker for clear cell carcinoma of the ovary. <i>Journal of Obstetrics and Gynaecology Research</i> , 2021, 47, 2978-2989.	1.3	4
26	Proposal for developing treatment algorithms of women with symptomatic adenomyosis: A singleâ€center experience. <i>Journal of Obstetrics and Gynaecology Research</i> , 2021, 47, 3257-3268.	1.3	2
27	Clinicopathological features of different subtypes in adenomyosis: Focus on early lesions. <i>PLoS ONE</i> , 2021, 16, e0254147.	2.5	9
28	A Novel Predictive Tool for Discriminating Endometriosis Associated Ovarian Cancer from Ovarian Endometrioma: The R2 Predictive Index. <i>Cancers</i> , 2021, 13, 3829.	3.7	9
29	Clinicopathological characteristics and imaging findings to identify adenomyosisâ€related symptoms. <i>Reproductive Medicine and Biology</i> , 2021, 20, 435-443.	2.4	5
30	A delicate redox balance between iron and heme oxygenase-1 as an essential biological feature of endometriosis. <i>Archives of Medical Research</i> , 2021, 52, 641-647.	3.3	9
31	Nonhormonal therapy for endometriosis based on energy metabolism regulation. <i>Reproduction and Fertility</i> , 2021, 2, C42-C57.	1.8	12
32	Tissue factor pathway inhibitor 2 as a serum marker for diagnosing asymptomatic venous thromboembolism in patients with epithelial ovarian cancer and positive Dâ€dimer results. <i>Molecular and Clinical Oncology</i> , 2021, 16, 46.	1.0	7
33	Preoperative plasma D-dimer level is a useful prognostic marker in ovarian cancer. <i>Journal of Obstetrics and Gynaecology</i> , 2020, 40, 102-106.	0.9	19
34	Mechanisms Underlying Adenomyosis-Related Fibrogenesis. <i>Gynecologic and Obstetric Investigation</i> , 2020, 85, 1-12.	1.6	22
35	Relationship between adenomyosis and endometriosis; Different phenotypes of a single disease?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 253, 191-197.	1.1	36
36	A Pathological Clarification of Sepsis-Associated Disseminated Intravascular Coagulation Based on Comprehensive Coagulation and Fibrinolysis Function. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1257-1269.	3.4	11

#	ARTICLE	IF	CITATIONS
37	A Classification Proposal for Adenomyosis Based on Magnetic Resonance Imaging. <i>Gynecologic and Obstetric Investigation</i> , 2020, 85, 118-126.	1.6	32
38	Brainstem Organoids From Human Pluripotent Stem Cells. <i>Frontiers in Neuroscience</i> , 2020, 14, 538.	2.8	43
39	Uterine adenomatoid tumor associated with lymph node lesions: a case report. <i>Abdominal Radiology</i> , 2020, 45, 2263-2267.	2.1	1
40	Shared Molecular Features Linking Endometriosis and Obstetric Complications. <i>Reproductive Sciences</i> , 2020, 27, 1089-1096.	2.5	6
41	A Relationship Between Endometriosis and Obstetric Complications. <i>Reproductive Sciences</i> , 2020, 27, 771-778.	2.5	31
42	Effect of the cyst fluid concentration of iron on infertility in patients with ovarian endometrioma. <i>World Academy of Sciences Journal</i> , 2020, 2, 1-1.	0.6	4
43	Two cases of ovarian cancer detected by endometrial cytology. <i>The Journal of the Japanese Society of Clinical Cytology</i> , 2020, 59, 299-304.	0.0	0
44	Tissue factor pathway inhibitor II as a specific biomarker for pre-operative prediction of clear-cell carcinoma of the ovary.. <i>Journal of Clinical Oncology</i> , 2020, 38, e18077-e18077.	1.6	0
45	Future Perspective of Clinical Application of the Minimally Invasive Laser Therapy Using Composite-type Optical Fiber for Endometrial Lesions. <i>Nippon Laser Igakkaishi</i> , 2020, 40, 386-391.	0.0	0
46	Development of the Composite-Type Optical Fiberscope for Medical Use. <i>Nippon Laser Igakkaishi</i> , 2020, 41, 18-24.	0.0	0
47	High-Quality Transmission of Cardiotocogram and Fetal Information Using a 5G System: Pilot Experiment. <i>JMIR Medical Informatics</i> , 2020, 8, e19744.	2.6	10
48	GSK-3 β mediates the effects of HNF-1 β overexpression in ovarian clear cell carcinoma. <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 122.	1.8	1
49	GSK-3 β mediates the effects of HNF-1 β overexpression in ovarian clear cell carcinoma. <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 1-1.	1.8	3
50	Modern approaches to noninvasive diagnosis of malignant transformation of endometriosis. <i>Oncology Letters</i> , 2019, 17, 1196-1202.	1.8	8
51	Magnetic resonance relaxometry improves the accuracy of conventional MRI in the diagnosis of endometriosis-associated ovarian cancer: A case report. <i>Molecular and Clinical Oncology</i> , 2019, 11, 296-300.	1.0	4
52	Immunohistochemical expression of CD44v9 and α HdG in ovarian endometrioma and the benign endometriotic lesions adjacent to clear cell carcinoma. <i>Journal of Obstetrics and Gynaecology Research</i> , 2019, 45, 2260-2266.	1.3	8
53	Involvement of Receptor for Advanced Glycation Endproducts in Hypertensive Disorders of Pregnancy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5462.	4.1	20
54	Guidelines for office gynecology in Japan: Japan Society of Obstetrics and Gynecology (JSOG) and Japan Association of Obstetricians and Gynecologists (JAOG) 2017 edition. <i>Journal of Obstetrics and Gynaecology Research</i> , 2019, 45, 766-786.	1.3	57

#	ARTICLE	IF	CITATIONS
55	Search for conditions to avoid parametrectomy during radical hysterectomy for cervical cancer. <i>Journal of Obstetrics and Gynaecology Research</i> , 2019, 45, 1371-1375.	1.3	2
56	Satisfaction of a new telephone consultation service for prenatal and postnatal health care. <i>Journal of Obstetrics and Gynaecology Research</i> , 2019, 45, 1376-1381.	1.3	19
57	Clinicopathological Characteristics of Atypical Glandular Cells Determined by Cervical Cytology in Japan: Survey of Gynecologic Oncology Data from the Obstetrical Gynecological Society of Kinki District, Japan. <i>Acta Cytologica</i> , 2019, 63, 361-370.	1.3	7
58	Preliminary evidence of a paternal-maternal genetic conflict on the placenta: Link between imprinting disorder and multi-generational hypertensive disorders. <i>Placenta</i> , 2019, 84, 69-73.	1.5	8
59	Magnetic resonance imaging findings for discriminating clear cell carcinoma and endometrioid carcinoma of the ovary. <i>Journal of Ovarian Research</i> , 2019, 12, 20.	3.0	15
60	Long-Term Follow-Up after Surgical Management for Atypical Endometriosis: A Series of Nine Cases. <i>Case Reports in Oncology</i> , 2019, 12, 76-83.	0.7	8
61	Subtype I (intrinsic) adenomyosis is an independent risk factor for dienogest-related serious unpredictable bleeding in patients with symptomatic adenomyosis. <i>Scientific Reports</i> , 2019, 9, 17654.	3.3	22
62	A diagnostic challenge of seromucinous borderline tumor. <i>Medicine (United States)</i> , 2019, 98, e15707.	1.0	6
63	Clinical significance of M2 macrophages expressing heme oxygenase-1 in malignant transformation of ovarian endometrioma. <i>Pathology Research and Practice</i> , 2019, 215, 639-643.	2.3	13
64	Integrating modern approaches to pathogenetic concepts of malignant transformation of endometriosis. <i>Oncology Reports</i> , 2019, 41, 1729-1738.	2.6	11
65	Discrimination of malignant transformation from benign endometriosis using a near-infrared approach. <i>Experimental and Therapeutic Medicine</i> , 2018, 15, 3000-3005.	1.8	3
66	Potential signaling pathways as therapeutic targets for overcoming chemoresistance in mucinous ovarian cancer (Review). <i>Biomedical Reports</i> , 2018, 8, 215-223.	2.0	9
67	Comparison of redox parameters in ovarian endometrioma and its malignant transformation. <i>Oncology Letters</i> , 2018, 16, 5257-5264.	1.8	11
68	Clear Cell Adenocarcinoma Arising from Endometriosis in the Groin: Wide Resection and Reconstruction with a Fascia Lata Tensor Muscle Skin Flap. <i>Case Reports in Obstetrics and Gynecology</i> , 2018, 2018, 1-4.	0.3	6
69	Conceptual frameworks of synthetic lethality in clear cell carcinoma of the ovary (Review). <i>Biomedical Reports</i> , 2018, 9, 112-118.	2.0	2
70	Uterine endometrial carcinoma with DNA mismatch repair deficiency: magnetic resonance imaging findings and clinical features. <i>Japanese Journal of Radiology</i> , 2018, 36, 429-436.	2.4	6
71	Factors that Differentiate between Endometriosis-associated Ovarian Cancer and Benign Ovarian Endometriosis with Mural Nodules. <i>Magnetic Resonance in Medical Sciences</i> , 2018, 17, 231-237.	2.0	35
72	Analysis of Risk Factors for Lymphatic Metastasis in Endometrial Carcinoma and Utility of Three-Dimensional Magnetic Resonance Imaging in Gynecology. <i>World Journal of Oncology</i> , 2018, 9, 74-79.	1.5	3

#	ARTICLE	IF	CITATIONS
73	The HNF-1 β -USP28-Caspin pathway upregulates DNA damage-induced Chk1 activation in ovarian clear cell carcinoma. <i>Oncotarget</i> , 2018, 9, 17512-17522.	1.8	28
74	Evaluation of vaginal fluid squamous cell carcinoma antigen test in diagnosis of premature rupture of membranes. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2017, 30, 334-337.	1.5	2
75	Role of Oxidative Stress in Epigenetic Modification in Endometriosis. <i>Reproductive Sciences</i> , 2017, 24, 1493-1502.	2.5	54
76	Skin-mucous membrane disorder and therapeutic effect of pegylated liposomal doxorubicin in recurrent ovarian cancer. <i>Journal of Obstetrics and Gynaecology Research</i> , 2017, 43, 1194-1199.	1.3	8
77	Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer. <i>Biomedical Reports</i> , 2017, 7, 391-399.	2.0	15
78	Sequential molecular changes and dynamic oxidative stress in high-grade serous ovarian carcinogenesis. <i>Free Radical Research</i> , 2017, 51, 755-764.	3.3	12
79	Final report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology, on a fact-finding questionnaire on the status of treatment of hereditary breast and ovarian cancer syndrome in Japan. <i>Journal of Obstetrics and Gynaecology Research</i> , 2017, 43, 1377-1380.	1.3	1
80	Squamous cell carcinoma antigen as a novel candidate marker for amniotic fluid embolism. <i>Journal of Obstetrics and Gynaecology Research</i> , 2017, 43, 1815-1820.	1.3	1
81	The conceptual advances of carcinogenic sequence model in high-grade serous ovarian cancer. <i>Biomedical Reports</i> , 2017, 7, 209-213.	2.0	15
82	A novel peptide blocking cancer cell invasion by structure-based drug design. <i>Biomedical Reports</i> , 2017, 7, 221-225.	2.0	2
83	Severe reduction of free-form ADAMTS13, unbound to von Willebrand factor, in plasma of patients with HELLP syndrome. <i>Blood Advances</i> , 2017, 1, 1628-1631.	5.2	11
84	Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux in women at risk after cesarean section. <i>Obstetrics and Gynecology Science</i> , 2017, 60, 535.	1.6	8
85	Case Report of Successful Childbearing after Conservative Surgery for Cervical Mullerian Adenosarcoma. <i>Case Reports in Obstetrics and Gynecology</i> , 2017, 2017, 1-4.	0.3	7
86	A Rare Case of Eggshell-Mimicking Omental Teratoma Treated with Laparoscopic Surgery. <i>Japanese Journal of Gynecology and Obstetric Endoscopy</i> , 2017, 33, 222-227.	0.0	1
87	Phenotypic characterization of adenomyosis occurring at the inner and outer myometrium. <i>PLoS ONE</i> , 2017, 12, e0189522.	2.5	43
88	A case of very early onset eclampsia, placental abruption and intrauterine fetal death. <i>Hypertension Research in Pregnancy</i> , 2017, 5, 17-19.	0.2	0
89	Transverse Relaxation Rate of Cyst Fluid Can Predict Malignant Transformation of Ovarian Endometriosis. <i>Magnetic Resonance in Medical Sciences</i> , 2017, 16, 137-145.	2.0	19
90	Comparison of the Different Definition Criteria for the Diagnosis of Amniotic Fluid Embolism. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2017, 11, QC18-QC21.	0.8	4

#	ARTICLE	IF	CITATIONS
91	Recent advances in targeting DNA-repair pathways for the treatment of ovarian cancer: introduction. <i>International Journal of Clinical Oncology</i> , 2017, 22, 609-610.	2.2	1
92	ç”£â© äºç\$è”ç™,ã,-ã,ãf%ãf©ã,ãf³â€•ã© äºç\$â-æ¥ç. 2017. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2017, 106,		
93	Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0165609.	2.5	23
94	Vaginal fluid pH and buffer capacity for predicting false preterm labor in Japanese women. <i>International Journal of Gynecology and Obstetrics</i> , 2016, 134, 69-74.	2.3	2
95	Cyst fluid hemoglobin species in endometriosis and its malignant transformation: The role of metallobiology. <i>Oncology Letters</i> , 2016, 11, 3384-3388.	1.8	24
96	Uterine carcinosarcoma including angiosarcoma: A short case report. <i>Pathology International</i> , 2016, 66, 598-599.	1.3	1
97	Walking Disability in Patients with Pelvic Insufficiency Fracture after Radiotherapy for Uterine Cervical Cancer. <i>Progress in Rehabilitation Medicine</i> , 2016, 1, n/a.	0.9	1
98	Efficacy of optical access trocar with Kocher clamps in obese women.. <i>Japanese Journal of Gynecologic and Obstetric Endoscopy</i> , 2016, 32, 162-166.	0.0	1
99	Sequential screening to predict symptomatic pulmonary thromboembolism after gynecologic surgery in Nara, Japan. <i>International Journal of Gynecology and Obstetrics</i> , 2016, 132, 42-45.	2.3	3
100	Potential scenarios leading to ovarian cancer arising from endometriosis. <i>Redox Report</i> , 2016, 21, 119-126.	4.5	38
101	Characterization of the down-regulated genes identified in preeclampsia placenta. <i>Hypertension in Pregnancy</i> , 2016, 35, 15-21.	1.1	10
102	Large cell neuroendocrine carcinoma of the endometrium. <i>The Journal of the Japanese Society of Clinical Cytology</i> , 2016, 55, 174-178.	0.0	0
103	Severe Reduction of Free ADAMTS13, Unbound to Von Willebrand Factor, in Plasma Milieu Is a Unique Feature of HELLP Syndrome. <i>Blood</i> , 2016, 128, 134-134.	1.4	0
104	Epigenetic dysregulation of endometriosis susceptibility genes (Review). <i>Molecular Medicine Reports</i> , 2015, 12, 1611-1616.	2.4	21
105	Checkpoint kinase 1 inhibitors as targeted molecular agents for clear cell carcinoma of the ovary. <i>Oncology Letters</i> , 2015, 10, 571-576.	1.8	8
106	Cyst fluid iron-related compounds as useful markers to distinguish malignant transformation from benign endometriotic cysts. <i>Cancer Biomarkers</i> , 2015, 15, 493-499.	1.7	30
107	Novel biomarker candidates for the diagnosis of ovarian clear cell carcinoma. <i>Oncology Letters</i> , 2015, 10, 612-618.	1.8	26
108	Contribution of protease system on human placentation. <i>Reproductive Immunology and Biology</i> , 2015, 30, 7-12.	0.2	0

#	ARTICLE	IF	CITATIONS
109	Amniotic Fluid Embolism. Obstetrical and Gynecological Survey, 2015, 70, 511-517.	0.4	14
110	Oxidative Stress and Antioxidant Defense in Endometriosis and Its Malignant Transformation. Oxidative Medicine and Cellular Longevity, 2015, 2015, 1-7.	4.0	84
111	Involvement of Visceral Adipose Tissue in Immunological Modulation of Inflammatory Cascade in Preeclampsia. Mediators of Inflammation, 2015, 2015, 1-10.	3.0	15
112	Design and Preclinical Validation of the Composite-Type Optical Fiberscope for Minimally Invasive Procedures of Intrauterine Disease. Journal of Minimally Invasive Gynecology, 2015, 22, 985-991.	0.6	4
113	Economic Burden of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery. Value in Health Regional Issues, 2015, 6, 73-79.	1.2	5
114	The Impact of Maternal-Fetal Genetic Conflict Situations on the Pathogenesis of Preeclampsia. Biochemical Genetics, 2015, 53, 223-234.	1.7	7
115	Addition of aprepitant to standard therapy for prevention of nausea and vomiting among patients with cervical cancer undergoing concurrent chemoradiotherapy. International Journal of Gynecology and Obstetrics, 2015, 131, 312-313.	2.3	3
116	Towards an understanding of the molecular mechanism of endometriosis: unbalancing epithelial-stromal genetic conflict. Gynecological Endocrinology, 2014, 30, 7-15.	1.7	22
117	Understanding the role of epigenomic, genomic and genetic alterations in the development of endometriosis (Review). Molecular Medicine Reports, 2014, 9, 1483-1505.	2.4	61
118	Inhibition of Cell Death and Induction of G2 Arrest Accumulation in Human Ovarian Clear Cells by HNF-1 β Transcription Factor: Chemosensitivity Is Regulated by Checkpoint Kinase CHK1. International Journal of Gynecological Cancer, 2014, 24, 838-843.	2.5	17
119	Vaginal delivery after placental abruption and intrauterine fetal death, including failed cases. International Journal of Gynecology and Obstetrics, 2014, 126, 180-181.	2.3	7
120	Mechanism of pain generation for endometriosis-associated pelvic pain. Archives of Gynecology and Obstetrics, 2014, 289, 13-21.	1.7	76
121	Genes Downregulated in Endometriosis Are Located Near the Known Imprinting Genes. Reproductive Sciences, 2014, 21, 966-972.	2.5	9
122	Fetal programming theory: Implication for the understanding of endometriosis. Human Immunology, 2014, 75, 208-217.	2.4	33
123	2P030 Ab initio molecular simulation for proposing novel peptide inhibitors blocking the ligand-binding to the receptor of cancer cell(O1B. Protein: Structure & Function,Poster,The 52nd) Tj ETQq1 1 0.784614 rgBT (Overlock		
124	Pathogenesis of endometriosis: The role of initial infection and subsequent sterile inflammation (Review). Molecular Medicine Reports, 2014, 9, 9-15.	2.4	103
125	Malignant Transformation of Endometriosis. , 2014, , 457-468.		1
126	Placental abruption with certified fetomaternal hemorrhage after traffic injury. Hypertension Research in Pregnancy, 2014, 2, 33-35.	0.2	1

#	ARTICLE	IF	CITATIONS
127	Palonosetron (PAL) in combination with 1-day versus 3-days dexamethasone (DEX) to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin (TC).. Journal of Clinical Oncology, 2014, 32, 9608-9608.	1.6	2
128	The prognostic factor of endometrial cancer receiving adjuvant taxane-platinum chemotherapy.. Journal of Clinical Oncology, 2014, 32, e16541-e16541.	1.6	0
129	Imprinting genes associated with endometriosis. EXCLI Journal, 2014, 13, 252-64.	0.7	9
130	Hereditary breast and ovarian cancer susceptibility genes (Review). Oncology Reports, 2013, 30, 1019-1029.	2.6	123
131	Toward an understanding of the pathophysiology of clear cell carcinoma of the ovary (Review). Oncology Letters, 2013, 6, 1163-1173.	1.8	19
132	New insights into the role of aminopeptidases in the treatment for both preeclampsia and preterm labor. Expert Opinion on Investigational Drugs, 2013, 22, 1425-1436.	4.1	4
133	The effects of vitronectin on specific interactions between urokinase-type plasminogen activator and its receptor:ab initiomolecular orbital calculations. Molecular Simulation, 2013, 39, 769-779.	2.0	4
134	Hepatocyte nuclear factor (HNF)-1 β and its physiological importance in endometriosis. Biomedical Reports, 2013, 1, 13-17.	2.0	11
135	The biology of uterine sarcomas: A review and update. Molecular and Clinical Oncology, 2013, 1, 599-609.	1.0	59
136	Prevention of cancer and inflammation by protease inhibitors. Frontiers in Bioscience - Elite, 2013, E5, 966-973.	1.8	26
137	Cytokines, proteases, and ligands of receptor for advanced glycation endproducts (RAGE) released by primary trophoblasts from human term placenta under hypoxic stimulation. Hypertension Research in Pregnancy, 2013, 1, 81-87.	0.2	1
138	Comparison of Neoadjuvant Intraarterial Chemotherapy Versus Concurrent Chemoradiotherapy in Patients With Stage IIIB Uterine Cervical Cancer. World Journal of Oncology, 2013, 4, 221-229.	1.5	2
139	Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. Modern Pathology, 2012, 25, 282-288.	5.5	170
140	The Dichotomy in the Histogenesis of Endometriosis-associated Ovarian Cancer. International Journal of Gynecological Pathology, 2012, 31, 304-312.	1.4	31
141	Identification of multiple pathways involved in the malignant transformation of endometriosis (Review). Oncology Letters, 2012, 4, 3-9.	1.8	46
142	Molecular Mechanisms Linking Endometriosis Under Oxidative Stress With Ovarian Tumorigenesis and Therapeutic Modalities. Cancer Investigation, 2012, 30, 473-480.	1.3	21
143	A potential link of oxidative stress and cell cycle regulation for development of endometriosis. Gynecological Endocrinology, 2012, 28, 897-902.	1.7	36
144	Modulation of estrogenic action in clear cell carcinoma of the ovary (Review). Experimental and Therapeutic Medicine, 2012, 3, 18-24.	1.8	24

#	ARTICLE	IF	CITATIONS
145	Peripheral RAGE (Receptor for Advanced Glycation Endproducts)-ligands in normal pregnancy and preeclampsia: novel markers of inflammatory response. <i>Journal of Reproductive Immunology</i> , 2012, 93, 69-74.	1.9	49
146	Identification of interleukin-6 (IL-6) and squamous cell carcinoma (SCC) as amniotic fluid-specific markers. <i>Open Journal of Obstetrics and Gynecology</i> , 2012, 02, 147-150.	0.2	4
147	Development of the Minimally Invasive Laser Therapy for Endometrial Lesions. <i>Nippon Laser Igakkaishi</i> , 2012, 33, 131-135.	0.0	0
148	Successful double filtration plasmapheresis treatment in an Rh(E)-incompatible pregnancy. <i>Nihon Toseki Igakkai Zasshi</i> , 2012, 45, 363-366.	0.1	0
149	Increase of high molecular weight adiponectin in hypertensive pregnancy was correlated with brain-type natriuretic peptide stimulation on adipocyte. <i>Pregnancy Hypertension</i> , 2011, 1, 200-205.	1.4	4
150	New insights into pattern recognition receptors and their ligands in gynecologic pathologies. <i>Human Immunology</i> , 2011, 72, 213-218.	2.4	11
151	A new approach regarding the treatment of preeclampsia and preterm labor. <i>Life Sciences</i> , 2011, 88, 17-23.	4.3	13
152	Risk of carcinoma in women with ovarian endometrioma. <i>Frontiers in Bioscience - Elite</i> , 2011, E3, 529-540.	1.8	24
153	The role of components of the chromatin modification machinery in carcinogenesis of clear cell carcinoma of the ovary (Review). <i>Oncology Letters</i> , 2011, 2, 591-597.	1.8	19
154	Molecular genetics and epidemiology of epithelial ovarian cancer (Review). <i>Oncology Reports</i> , 2011, 26, 1347-56.	2.6	37
155	Redox-Active Iron-Induced Oxidative Stress in the Pathogenesis of Clear Cell Carcinoma of the Ovary. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1.	2.5	46
156	Inflammatory pattern recognition receptors and their ligands: factors contributing to the pathogenesis of preeclampsia. <i>Inflammation Research</i> , 2011, 60, 509-520.	4.0	21
157	New insights into the pathophysiology of endometriosis: from chronic inflammation to danger signal. <i>Gynecological Endocrinology</i> , 2011, 27, 73-79.	1.7	81
158	Anticytokine Therapy in Preterm Labor: Current Knowledge and Future Perspectives. <i>Gynecologic and Obstetric Investigation</i> , 2011, 71, 1-10.	1.6	4
159	Search for Amniotic Fluid-Specific Markers: Novel Biomarker Candidates for Amniotic Fluid Embolism. <i>The Open Women's Health Journal</i> , 2011, 5, 7-15.	0.5	5
160	Clear cell carcinoma of the ovary: Potential pathogenic mechanisms (Review). <i>Oncology Reports</i> , 2010, 23, 1193-203.	2.6	56
161	Anti-inflammatory actions of serine protease inhibitors containing the Kunitz domain. <i>Inflammation Research</i> , 2010, 59, 679-687.	4.0	59
162	Screening, epidemiology, molecular biology, and treatment strategies for endometriosis-associated ovarian cancer. <i>Reproductive Medicine and Biology</i> , 2010, 9, 17-22.	2.4	4

#	ARTICLE	IF	CITATIONS
163	Fatal Factors of Clinical Manifestations and Laboratory Testing in Patients with Amniotic Fluid Embolism. <i>Gynecologic and Obstetric Investigation</i> , 2010, 70, 138-144.	1.6	28
164	Physiological and pathophysiological roles of placental aminopeptidase in maternal sera: possible relation to preeclampsia and preterm delivery. <i>Expert Opinion on Medical Diagnostics</i> , 2009, 3, 479-491.	1.6	5
165	The effect of recombinant aminopeptidase A (APA) on hypertension in pregnant spontaneously hypertensive rats (SHRs). <i>Early Human Development</i> , 2009, 85, 589-594.	1.8	7
166	Ovarian cancer in endometriosis: epidemiology, natural history, and clinical diagnosis. <i>International Journal of Clinical Oncology</i> , 2009, 14, 378-382.	2.2	76
167	Theoretical model of treatment strategies for clear cell carcinoma of the ovary: Focus on perspectives. <i>Cancer Treatment Reviews</i> , 2009, 35, 608-615.	7.7	34
168	Oxytocin hypersensitivity in pregnant P-LAP deficient mice. <i>Life Sciences</i> , 2009, 84, 668-672.	4.3	10
169	The role of iron in the pathogenesis of endometriosis. <i>Gynecological Endocrinology</i> , 2009, 25, 39-52.	1.7	78
170	The Role of Hepatocyte Nuclear Factor- β in the Pathogenesis of Clear Cell Carcinoma of the Ovary. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 471-479.	2.5	60
171	Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary (review). <i>Oncology Reports</i> , 2009, 22, 233-40.	2.6	64
172	Peritoneal disseminated recurrence and lung metastasis after surgery for stage IA uterine papillary serous carcinoma of the endometrium: a case report. <i>Archives of Gynecology and Obstetrics</i> , 2008, 278, 277-280.	1.7	0
173	Clinicopathologic features of ovarian cancer in patients with ovarian endometrioma. <i>Journal of Obstetrics and Gynaecology Research</i> , 2008, 34, 872-877.	1.3	48
174	Ovarian endometrioma—Risks factors of ovarian cancer development. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2008, 138, 187-193.	1.1	140
175	Molecular structure and function analysis of bikunin on down-regulation of tumor necrosis factor- α expression in activated neutrophils. <i>Cytokine</i> , 2008, 42, 191-197.	3.2	9
176	Prevalence of Ovarian Cancer among Women with a CA125 Level of 35 U/ml or Less. <i>Gynecologic and Obstetric Investigation</i> , 2008, 65, 133-138.	1.6	7
177	Bikunin suppresses expression of pro-inflammatory cytokines induced by lipopolysaccharide in neutrophils. <i>Journal of Endotoxin Research</i> , 2007, 13, 369-376.	2.5	13
178	Essential role of placental leucine aminopeptidase in gynecologic malignancy. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 453-461.	3.4	38
179	Enhanced spontaneous metastasis in bikunin-deficient mice. <i>International Journal of Cancer</i> , 2006, 118, 2322-2328.	5.1	15
180	Endogenous anti-inflammatory substances, inter- α -inhibitor and bikunin. <i>Biological Chemistry</i> , 2006, 387, 1545-1549.	2.5	25

#	ARTICLE	IF	CITATIONS
181	DIETARY SUPPLEMENTATION OF SOYBEAN KUNITZ TRYPSIN INHIBITOR REDUCES LIPOPOLYSACCHARIDE-INDUCED LETHALITY IN MOUSE MODEL. <i>Shock</i> , 2005, 23, 441-447.	2.1	9
182	Suppression of lipopolysaccharide-induced cytokine production of gingival fibroblasts by a soybean, Kunitz trypsin inhibitor. <i>Journal of Periodontal Research</i> , 2005, 40, 461-468.	2.7	19
183	A soybean Kunitz trypsin inhibitor reduces tumor necrosis factor-alpha production in ultraviolet-exposed primary human keratinocytes. <i>Experimental Dermatology</i> , 2005, 14, 051014080045005.	2.9	7
184	Suppressing effects of daily oral supplementation of beta-glucan extracted from <i>Agaricus blazei</i> Murill on spontaneous and peritoneal disseminated metastasis in mouse model. <i>Journal of Cancer Research and Clinical Oncology</i> , 2005, 131, 527-538.	2.5	89
185	Bikunin Suppresses Lipopolysaccharide-Induced Lethality through Down-Regulation of Tumor Necrosis Factor- α and Interleukin-1 β in Macrophages. <i>Journal of Infectious Diseases</i> , 2005, 191, 930-938.	4.0	42
186	Suppression of Urokinase Receptor Expression by Thalidomide Is Associated with Inhibition of Nuclear Factor κ B Activation and Subsequently Suppressed Ovarian Cancer Dissemination. <i>Cancer Research</i> , 2005, 65, 10464-10471.	0.9	17
187	Genetic Down-regulation of Phosphoinositide 3-Kinase by Bikunin Correlates with Suppression of Invasion and Metastasis in Human Ovarian Cancer HRA Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 6371-6379.	3.4	13
188	Bikunin Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor Alpha Induction in Macrophages. <i>Vaccine Journal</i> , 2004, 11, 1140-1147.	2.6	27
189	A soybean Kunitz trypsin inhibitor suppresses ovarian cancer cell invasion by blocking urokinase upregulation. <i>Clinical and Experimental Metastasis</i> , 2004, 21, 159-166.	3.3	74
190	Therapeutic efficacy of once-daily oral administration of a Kunitz-type protease inhibitor, bikunin, in a mouse model and in human cancer. <i>Cancer</i> , 2004, 100, 869-877.	4.1	33
191	Bikunin plus paclitaxel markedly reduces tumor burden and ascites in mouse model of ovarian cancer. <i>International Journal of Cancer</i> , 2004, 110, 134-139.	5.1	20
192	Suppressing effects of dietary supplementation of soybean trypsin inhibitor on spontaneous, experimental and peritoneal disseminated metastasis in mouse model. <i>International Journal of Cancer</i> , 2004, 112, 519-524.	5.1	28
193	The Protease Inhibitor Bikunin, a Novel Anti-Metastatic Agent. <i>Biological Chemistry</i> , 2003, 384, 749-54.	2.5	63
194	Bikunin Target Genes in Ovarian Cancer Cells Identified by Microarray Analysis. <i>Journal of Biological Chemistry</i> , 2003, 278, 14640-14646.	3.4	44
195	A Kunitz-type Protease Inhibitor, Bikunin, Inhibits Ovarian Cancer Cell Invasion by Blocking the Calcium-dependent Transforming Growth Factor- β 1 Signaling Cascade. <i>Journal of Biological Chemistry</i> , 2003, 278, 7790-7799.	3.4	56
196	Kunitz-type Protease Inhibitor Bikunin Disrupts Phorbol Ester-induced Oligomerization of CD44 Variant Isoforms Containing Epitope v9 and Subsequently Suppresses Expression of Urokinase-type Plasminogen Activator in Human Chondrosarcoma Cells. <i>Journal of Biological Chemistry</i> , 2002, 277, 8022-8032.	3.4	28
197	CD44 stimulation by fragmented hyaluronic acid induces upregulation of urokinase-type plasminogen activator and its receptor and subsequently facilitates invasion of human chondrosarcoma cells. <i>International Journal of Cancer</i> , 2002, 102, 379-389.	5.1	51
198	Suppression of urokinase receptor expression by bikunin is associated with inhibition of upstream targets of extracellular signal-regulated kinase-dependent cascade. <i>FEBS Journal</i> , 2002, 269, 3945-3957.	0.2	41

#	ARTICLE	IF	CITATIONS
199	Structure and function analysis of urinary trypsin inhibitor (UTI): identification of binding domains and signaling property of UTI by analysis of truncated proteins. <i>BBA - Proteins and Proteomics</i> , 2001, 1547, 26-36.	2.1	28
200	Characterization of Binding Properties of Urinary Trypsin Inhibitor to Cell-associated Binding Sites on Human Chondrosarcoma Cell Line HCS-2/8. <i>Journal of Biological Chemistry</i> , 2001, 276, 13650-13656.	3.4	28
201	Syndecan-4 deficiency impairs the fetal vessels in the placental labyrinth. <i>Developmental Dynamics</i> , 2000, 219, 539-544.	1.8	66
202	Identification and characterization of a Kunitz-type protease inhibitor in ascites fluid from patients with ovarian carcinoma. <i>International Journal of Cancer</i> , 2000, 87, 44-54.	5.1	8
203	Suppression of urokinase-type plasminogen activator expression from human ovarian cancer cells by urinary trypsin inhibitor. <i>BBA - Proteins and Proteomics</i> , 2000, 1481, 310-316.	2.1	22
204	Identity of Urinary Trypsin Inhibitor-binding Protein to Link Protein. <i>Journal of Biological Chemistry</i> , 2000, 275, 21185-21191.	3.4	41
205	Activated protein C suppresses tissue factor expression on U937 cells in the endothelial protein C receptor-dependent manner. <i>FEBS Letters</i> , 2000, 477, 208-212.	2.8	66
206	Identification of Link Protein during Follicle Development and Cumulus Cell Cultures in Rats. <i>Endocrinology</i> , 1999, 140, 3835-3842.	2.8	26
207	Localization and Interaction of Hyaluronic Acid and Inter- α -Trypsin Inhibitor in Stimulated Preovulatory Rat Ovaries.. <i>Acta Histochemica Et Cytochemica</i> , 1999, 32, 65-71.	1.6	1
208	Identification of Link Protein during Follicle Development and Cumulus Cell Cultures in Rats. <i>Endocrinology</i> , 1999, 140, 3835-3842.	2.8	8
209	Identification and characterization of the cell-associated binding protein for urinary trypsin inhibitor. <i>BBA - Proteins and Proteomics</i> , 1998, 1383, 253-268.	2.1	27
210	Serological and Immunohistochemical Diagnosis of Amniotic Fluid Embolism. <i>Seminars in Thrombosis and Hemostasis</i> , 1998, 24, 479-484.	2.7	62
211	REGULATION OF EXTRACELLULAR MATRIX STABILIZATION: BINDING OF INTER- α -TRYPSIN INHIBITOR WITH HYALURONIC ACID. <i>Biomedical Research</i> , 1998, 19, 183-190.	0.9	1
212	Histological diagnosis of amniotic fluid embolism by monoclonal antibody TKH-2 that recognizes NeuAc β 2 α 6GalNAc epitope. <i>Human Pathology</i> , 1997, 28, 428-433.	2.0	58
213	Hyaluronic acid-specific regulation of cytokines by human uterine fibroblasts. <i>American Journal of Physiology - Cell Physiology</i> , 1997, 273, C1151-C1159.	4.6	89
214	Cell-associated Fibrinolysis in Tumor Cell Invasion and Metastasis. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 1996, 7, 154-158.	0.1	0
215	Inhibition of metastasis of lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. <i>International Journal of Cancer</i> , 1994, 57, 727-733.	5.1	91
216	Analysis of monoclonal antibodies reactive with meconium- and amniotic fluid-derived mucin. <i>Journal of Clinical Laboratory Analysis</i> , 1994, 8, 27-34.	2.1	3

#	ARTICLE	IF	CITATIONS
217	Inhibition of the Metastasis of Lewis Lung Carcinoma by Antibody Against Urokinase-Type Plasminogen Activator in the Experimental and Spontaneous Metastasis Model. <i>Thrombosis and Haemostasis</i> , 1994, 71, 474-480.	3.4	53
218	Quantitative and qualitative assessment of CA-125 production by human endometrial epithelial cells: Comparison of eutopic and heterotopic epithelial cells. <i>International Journal of Cancer</i> , 1993, 54, 426-434.	5.1	5
219	Increased Cell-surface Urokinase in Advanced Ovarian Cancer. <i>Japanese Journal of Cancer Research</i> , 1993, 84, 633-640.	1.7	31
220	A simple, noninvasive, sensitive method for diagnosis of amniotic fluid embolism by monoclonal antibody TKH-2 that recognizes NeuAc1±2-6GalNAc. <i>American Journal of Obstetrics and Gynecology</i> , 1993, 168, 848-853.	1.3	79
221	Activation of Receptor-bound Single-chain Urokinase-type Plasminogen Activator by Plasmin. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 1993, 4, 170-178.	0.1	0
222	Prevention by Urinastatin of <i>Cis</i> -Diamminedichloroplatinum-Induced Nephrotoxicity in Rabbits: Comparison of Urinary Enzyme Excretions and Morphological Alterations by Electron Microscopy. <i>Asia-Oceania Journal of Obstetrics and Gynaecology</i> , 1991, 17, 277-288.	0.0	9
223	Immune-related pathophysiological causes relevant to a subset of patients with preeclampsia (Review). <i>World Academy of Sciences Journal</i> , 0, , .	0.6	2
224	Somatic driver mutations in endometriosis as possible regulators of fibrogenesis (Review). <i>World Academy of Sciences Journal</i> , 0, , .	0.6	3
225	Towards an understanding of the molecular mechanisms of endometriosis-associated symptoms (Review). <i>World Academy of Sciences Journal</i> , 0, , .	0.6	6
226	Impact of reorganized interfacility transfer on emergency obstetric care in Nara prefecture, Japan. <i>World Academy of Sciences Journal</i> , 0, , .	0.6	0
227	Bioinformatics strategy for the screening of key genes to differentiate adenomyosis from endometriosis (Review). <i>World Academy of Sciences Journal</i> , 0, , .	0.6	1
228	Office diagnostic smart hysteroscopy, hysmartscopy, using mobile technology: A single center experience and analysis of diagnostic accuracy. <i>World Academy of Sciences Journal</i> , 0, , .	0.6	0